Novartis India Stake Sale: Stock Surges 18% on ₹1,446 Cr Deal

Introduction

Swiss pharmaceutical major Novartis AG has announced its decision to sell its entire 70.68% stake in its publicly listed Indian arm, Novartis India Limited, for approximately ₹1,446 crore. The stake will be acquired by a consortium led by private equity firm ChrysCapital. This move triggered a mandatory open offer for public shareholders and resulted in an 18% surge in Novartis India's share price, reflecting significant investor interest in the change of control.

The Acquisition Agreement

The definitive agreement involves the sale of 1,74,50,680 equity shares held by Novartis AG. The acquiring consortium includes WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners. This divestment is the culmination of a strategic review that Novartis AG initiated in February 2024, aimed at realigning its global operations. The company stated that this transaction helps complete its transformation into a 'pure-play innovative medicines company' and aligns its footprint for sustainable long-term growth.

Mandatory Open Offer Details

As per SEBI's takeover regulations, the acquisition of a controlling stake triggers a mandatory open offer to the public shareholders. The consortium has consequently announced an offer to acquire up to an additional 26% of Novartis India's voting share capital. This translates to 64,19,608 equity shares. The open offer price has been fixed at ₹860.64 per share, representing a 3.64% premium over the closing price of ₹830.45 on the day before the announcement. The total consideration for the open offer, if fully subscribed, will amount to ₹552.49 crore, payable in cash.

Financials of the Transaction

The deal is structured in two parts: the primary stake sale from the promoter and the subsequent open offer to the public. The underlying transaction for the 70.68% stake is valued at ₹1,445.89 crore. The open offer for the 26% stake is valued at ₹552.49 crore.

Interestingly, the share purchase agreement reveals a differentiated pricing structure for the consortium members acquiring the promoter's stake.

Market Reaction and Stock Performance

The announcement was met with strong positive sentiment from the market. On February 20, 2026, the day of the news, shares of Novartis India surged by as much as 20%, hitting the upper circuit at ₹996.50 on the BSE. This was significantly above the open offer price, suggesting that investors anticipate further value creation under the new ownership.

Post-Acquisition Structure and Future Outlook

Upon completion of the transaction, the ChrysCapital-led consortium will become the new promoter of Novartis India. Novartis AG will cease to be the promoter and will be reclassified under the public shareholder category. If the open offer is fully subscribed, the new promoters' combined holding will increase to 96.68%. If no shares are tendered, their stake will remain at 70.68%. The acquirers have clarified that they do not intend to delist the company and will take necessary steps to comply with the minimum 25% public shareholding norm if required. As part of the agreement, Novartis India will change its name to remove all references to the Novartis brand within 120 days of the deal's closing.

Timeline and Next Steps

The transaction is subject to the satisfaction of certain conditions and is expected to close in the third quarter of 2026. According to the detailed public statement, the tendering period for the open offer is scheduled to commence on April 21, 2026, and will close on May 5, 2026. This period will be crucial for public shareholders to decide whether to tender their shares or remain invested under the new management.

Conclusion

The sale of Novartis AG's stake marks a significant turning point for Novartis India, transitioning ownership from a global pharmaceutical giant to a private equity-led consortium. The deal structure, including the mandatory open offer, provides an exit opportunity for public shareholders at a premium. The market's enthusiastic response indicates confidence in the company's future prospects under its new leadership, which will be tasked with steering the company's strategic direction and operational performance going forward.